Barbara Willekens, Inez Wens, Kristien Wouters, Patrick Cras, Nathalie Cools
In the past years, translational approaches have led to early-stage clinical trials assessing safety and efficacy of tolerance-inducing cell-based treatments in patients. This review aims to determine if tolerance-inducing cell-based therapies, including dendritic cells, regulatory T cells and mesenchymal stem cells, are safe in adult patients who underwent organ transplantation or in those with autoimmune diseases, including multiple sclerosis, diabetes mellitus type 1, Crohn's disease and rheumatoid arthritis...
June 10, 2021: Autoimmunity Reviews
Xindi Li, Chengyi Zhang, Dongmei Jia, Moli Fan, Ting Li, De-Cai Tian, Yaou Liu, Fu-Dong Shi
BACKGROUND: Despite inclusion in neuromyelitis optica spectrum disorders (NMOSD), myelin oligodendrocyte glycoprotein antibody (MOG-Ab)-associated diseases are increasingly recognized as an independent disease entity. In this study, we conducted a systematic review and meta-analysis to comprehensively update the rate of occurrence of MOG-Ab in Aquaporin4 (AQP4)-antibody seronegative NMOSD. METHODS: We searched PubMed, EMBASE, and Cochrane databases for studies reporting the rates of patients with MOG-Ab in NMOSD...
May 28, 2021: Multiple Sclerosis and related Disorders
Chieh-Hsin Lee, Bei Jiang, Maryam Nakhaei-Nejad, David Barilla, Gregg Blevins, Fabrizio Giuliani
BACKGROUND: Relapsing-remitting multiple sclerosis (RRMS) is an autoimmune disorder of the central nervous system. Dimethyl Fumarate is a disease-modifying medication used to treat RRMS patients that can induce lymphopenia. We aimed to immunophenotype peripheral blood mononuclear cells (PBMC) in RRMS patients cross-sectionally and examine the characteristics and modifications of lymphopenia over time. METHODS: Characterization of PBMC was done by multiparametric flow cytometry...
May 7, 2021: Multiple Sclerosis and related Disorders
Julie van der Zee, Lubina Dillen, Yalda Baradaran-Heravi, Helena Gossye, Cemile Kocoglu, Ivy Cuyt, Bart Dermaut, Anne Sieben, Jonathan Baets, Peter De Jonghe, Rik Vandenberghe, Peter De Deyn, Patrick Cras, Sebastiaan Engelborghs, Christine Van Broeckhoven
Neurodegenerative disorders like frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS) are pathologically characterized by toxic protein deposition in the cytoplasm or nucleus of affected neurons and glial cells. Many of these aggregated proteins belong to the class of RNA binding proteins (RBP), and, when mutated, account for a significant subset of familial ALS and FTD cases. Here, we present first genetic evidence for the RBP gene RBM45 in the FTD-ALS spectrum. RBM45 shows many parallels with other FTD-ALS associated genes and proteins...
June 9, 2021: Neurobiology of Disease
Nils Koch-Henriksen, Per Soelberg Sørensen, Melinda Magyari
OBJECTIVE: Whether relapses have direct effects on permanent disability in multiple sclerosis is still an unsettled issue. We aimed at investigating the cumulative effect of breakthrough relapses on the Expanded Disability Status Scale (EDSS) in relapsing-onset MS patients under disease modifying therapy (DMT). METHODS: From the Danish Multiple Sclerosis Registry we identified all patients in Denmark with relapsing-onset MS who had started DMT and followed them from the first day of treatment...
May 17, 2021: Multiple Sclerosis and related Disorders
Johanna B Andersen, Sifat Sharmin, Mathilde Lefort, Nils Koch-Henriksen, Finn Sellebjerg, Per Soelberg Sørensen, Claudia C Hilt Christensen, Peter V Rasmussen, Michael B Jensen, Jette L Frederiksen, Stephan Bramow, Henrik K Mathiesen, Karen I Schreiber, Dana Horakova, Eva K Havrdova, Raed Alroughani, Guillermo Izquierdo, Sara Eichau, Serkan Ozakbas, Francesco Patti, Marco Onofrj, Alessandra Lugaresi, Murat Terzi, Pierre Grammond, Francois Grand Maison, Bassem Yamout, Alexandre Prat, Marc Girard, Pierre Duquette, Cavit Boz, Maria Trojano, Pamela McCombe, Mark Slee, Jeannette Lechner-Scott, Recai Turkoglu, Patrizia Sola, Diana Ferraro, Franco Granella, Vahid Shaygannejad, Julie Prevost, Olga Skibina, Claudio Solaro, Rana Karabudak, Bart V Wijmeersch, Tunde Csepany, Daniele Spitaleri, Steve Vucic, Romain Casey, Marc Debouverie, Gilles Edan, Jonathan Ciron, Aurélie Ruet, Jérôme D Sèze, Elisabeth Maillart, Hélène Zephir, Pierre Labauge, Gilles Defer, Christine Lebrun, Thibault Moreau, Eric Berger, Pierre Clavelou, Jean Pelletier, Bruno Stankoff, Olivier Gout, Eric Thouvenot, Olivier Heinzlef, Abdullatif Al-Khedr, Bertrand Bourre, Olivier Casez, Philippe Cabre, Alexis Montcuquet, Abir Wahab, Jean-Philippe Camdessanché, Aude Marousset, Ivania Patry, Karolina Hankiewicz, Corinne Pottier, Nicolas Maubeuge, Céline Labeyrie, Chantal Nifle, Emmanuelle Leray, David A Laplaud, Helmut Butzkueven, Tomas Kalincik, Sandra Vukusic, Melinda Magyari
BACKGROUND: Natalizumab and fingolimod were the first preparations recommended for disease breakthrough in priorly treated relapsing-remitting multiple sclerosis. Of three published head-to-head studies two showed that natalizumab is the more effective to prevent relapses and EDSS worsening. METHODS: By re-analyzing original published results from MSBase, France, and Denmark using uniform methodologies, we aimed at identifying the effects of differences in methodology, in the MS-populations, and at re-evaluating the differences in effectiveness between the two drugs...
May 8, 2021: Multiple Sclerosis and related Disorders
Miceline Mésidor, Marie-Pierre Sylvestre, Marie-Claude Rousseau, Elaine Roger, Pierre Duquette
BACKGROUND: The few observational studies that investigated the long-term effects of interferon-beta and glatiramer acetate were usually focused on progression to irreversible disability and other outcomes such as number of relapses and transition to secondary-progressive multiple sclerosis (SPMS) have been rarely studied. The objective of this paper is to estimate the effect of interferon-beta/glatiramer acetate on progression to irreversible disability, transition from relapsing-remitting multiple sclerosis (RRMS) to SPMS and the rate of relapses over 10 years...
May 30, 2021: Multiple Sclerosis and related Disorders
Zahra Salehi, Mohammad Keramatipour, Saeed Talebi, S Shahriar Arab, Abdorreza Naser Moghadasi, Mohammad Ali Sahraian, Maryam Izad
The prevalence of familial multiple sclerosis (FMS) is increasing worldwide which endorses the heritability of the disease. Given that many genome variations are ethnicity-specific and consanguineous marriage could affect genetic diseases, hereditary disease gene analysis among FMS patients from Iran, a country with high rates of parental consanguinity, could be highly effective in finding mutations underlying disease pathogenesis. To examine rare genetic mutations, we selected three Iranian FMS cases with ≥3 MS patients in more than one generation and performed whole exome sequencing...
June 8, 2021: Genomics
Moon Hee Hur
Pediatric demyelinating syndromes are a spectrum of diseases affecting the central nervous system. In the past decade, major advances have been made in this field, including the discovery of antibody-based biomarkers and treatment guidelines for specific syndromes. When myelin oligodendrocyte glycoprotein (MOG) antibodies were first discovered, they were thought to be a biomarker for multiple sclerosis (MS). However, further research has shown that MOG positivity during the first episode of a pediatric demyelinating syndrome is a predictor of a course that is distinct to MS...
June 2021: Pediatric Annals
Mahsa Samangooei, Mojtaba Farjam, Zahra Niknam, Masoud Etemadifar, Mohammad Hasan Meshkibaf, Saam Noroozi
Matrix metalloproteinase, especially Matrix metalloproteinase-9 (MMP-9) has vital roles in the disruption of blood barrier, neuroinflammation and pathogenesis of multiple sclerosis (MS) patients. The goal of this study is to estimate the plasma levels of MMP-9 in the first-degree family of MS patients. 35 untreated patients with definite RRMS (Relapsing-Remitting Multiple sclerosis) according to the McDonald criteria, 24 healthy controls (HC) and 26 high-risk families of untreated RRMS patients were enrolled in the study...
June 11, 2021: Metabolic Brain Disease
M Frosch, N Kremers, K Lisko, H Urbach, M Prinz, C A Taschner
No abstract text is available yet for this article.
June 11, 2021: Clinical Neuroradiology
Priyanka Devi-Marulkar, Carolina Moraes-Cabe, Pascal Campagne, Béatrice Corre, Aida Meghraoui-Kheddar, Vincent Bondet, Alba Llibre, Darragh Duffy, Elisabeth Maillart, Caroline Papeix, Sandra Pellegrini, Frédérique Michel
Background: Interferon beta (IFN β ) has been prescribed as a first-line disease-modifying therapy for relapsing-remitting multiple sclerosis (RRMS) for nearly three decades. However, there is still a lack of treatment response markers that correlate with the clinical outcome of patients. Aim: To determine a combination of cellular and molecular blood signatures associated with the efficacy of IFN β treatment using an integrated approach. Methods: The immune status of 40 RRMS patients, 15 of whom were untreated and 25 that received IFN β 1a treatment (15 responders, 10 non-responders), was investigated by phenotyping regulatory CD4+ T cells and naïve/memory T cell subsets, by measurement of circulating IFN α / β proteins with digital ELISA (Simoa) and analysis of ~600 immune related genes including 159 interferon-stimulated genes (ISGs) with the Nanostring technology...
2021: Frontiers in Immunology
Dániel Pukoli, Helga Polyák, Cecilia Rajda, László Vécsei
Multiple sclerosis is an autoimmune, demyelinating, and neurodegenerative disease of the central nervous system. In recent years, it has been proven that the kynurenine system plays a significant role in the development of several nervous system disorders, including multiple sclerosis. Kynurenine pathway metabolites have both neurotoxic and neuroprotective effects. Moreover, the enzymes of the kynurenine pathway play an important role in immunomodulation processes, among others, as well as interacting with neuronal energy balance and various redox reactions...
2021: Frontiers in Neuroscience
Tiziana Lencioni, Denise Anastasi, Ilaria Carpinella, Anna Castagna, Alessandro Crippa, Elisa Gervasoni, Alberto Marzegan, Marco Rabuffetti, Elisa Pelosin, Davide Cattaneo, Maurizio Ferrarin
Maintaining a stable gait requires a dynamic balance control, that can be altered in persons with Multiple Sclerosis (MS), Stroke (ST), and Parkinson's disease (PD). The understanding of the strategy for Center of Mass (CoM) positioning adopted by patients during walking is important to be able to program treatments aimed at improving gait control and preventing falls. Forty-four persons with a mild-to-moderate neurological disorder (20 with MS, 14 with ST, 10 with PD) underwent clinical examination and gait analysis...
June 11, 2021: Proceedings of the Institution of Mechanical Engineers. Part H, Journal of Engineering in Medicine
Dilek Demirtepe-Saygılı
The study aims to investigate Multiple Sclerosis (MS) experiences of couples. Using a dyadic qualitative method, separate simultaneous interviews were conducted with 20 couples, including one partner with MS. The themes resulting from content analysis were examined in two categories: Convergent (anxiety about future, acceptance of MS and MS as an accelerator of the relationship) and divergent (sexual problems, the experience of MS symptoms, the priority of the problems and untold issues). The findings revealed shared and unique perspectives of partners in the illness process, having the potential to guide the psychosocial interventions for couples living with a chronic illness...
June 11, 2021: Journal of Health Psychology
Alex Exuzides, Daniel Sheinson, Paris Sidiropoulos, Fabio Magrini, Shervin Gholizadeh, Andy Surinach, Lawrence Cook, Craig S Meyer, Michael Yeaman
BACKGROUND: Neuromyelitis optica spectrum disorder (NMOSD) is associated with various comorbidities, including non-autoimmune and autoimmune conditions. The burden and cost of illness for NMOSD are unclear, particularly in the context of comorbidities. METHODS: Claims data from IBM MarketScan Commercial and Medicare Supplemental Databases between 2014 and 2018 were analyzed. Patients with NMOSD were specified as having inpatient or outpatient claims for NMOSD diagnosis or specific NMOSD symptoms claims and no subsequent claims for multiple sclerosis (MS) or use of MS disease-modifying therapy (DMT)...
June 3, 2021: Journal of the Neurological Sciences
Mladen Rakić, Sophie Vercruyssen, Simon Van Eyndhoven, Ezequiel de la Rosa, Saurabh Jain, Sabine Van Huffel, Frederik Maes, Dirk Smeets, Diana M Sima
Multiple sclerosis (MS) is a chronic autoimmune, inflammatory neurological disease of the central nervous system. Its diagnosis nowadays commonly includes performing an MRI scan, as it is the most sensitive imaging test for MS. MS plaques are commonly identified from fluid-attenuated inversion recovery (FLAIR) images as hyperintense regions that are highly varying in terms of their shapes, sizes and locations, and are routinely classified in accordance to the McDonald criteria. Recent years have seen an increase in works that aimed at development of various semi-automatic and automatic methods for detection, segmentation and classification of MS plaques...
June 4, 2021: NeuroImage: Clinical
Nadine Akbar, Marcia Finlayson
BACKGROUND: Cognitive difficulties are commonly reported in persons with multiple sclerosis (MS), however, self-reports of cognition often do not correspond well to objective neuropsychological test performance. The use of qualitative interviews can allow for persons with MS to describe in more detail how their cognitive function is impacted in daily life while also taking into consideration personal and environmental influences. No study to our knowledge has examined the association between objective neuropsychological test performance and qualitative interview reports of daily cognitive function...
March 19, 2021: Multiple Sclerosis and related Disorders
Heidi Øyen Flemmen, Cecilia Smith Simonsen, Line Broch, Cathrine Brunborg, Pål Berg-Hansen, Stine Marit Moen, Hege Kersten, Elisabeth Gulowsen Celius
OBJECTIVE: The identification of potential risk factors for disease severity is of great importance in the treatment of multiple sclerosis. The influence of socioeconomic status on progression in multiple sclerosis (MS) is sparsely investigated. Our aim was to investigate how socioeconomic status in adolescence influences disease progression in later life. METHODS: A total of 1598 patients with multiple sclerosis from a well-defined population in Norway were included...
May 30, 2021: Multiple Sclerosis and related Disorders
Carol Chase Huizar, Niannian Ji, Robert Reddick, Gary R Ostroff, Thomas G Forsthuber
For over 70 years experimental autoimmune encephalomyelitis (EAE) has been induced with myelin autoantigens emulsified in complete Freund's adjuvant (CFA) which has significant side effects such as pain, inflammation, and tissue necrosis at the injection site. β-1,3-d-glucan particles (GPs) are hollow microcapsules prepared from Saccharomyces cerevisiae cell walls that induce potent Th17 cell responses without causing strong injection site tissue reactions. We evaluated the potential of GPs complexed with neuroantigens to induce EAE while avoiding undesirable side effects...
May 21, 2021: Cellular Immunology
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read

Save your favorite articles in one place with a free QxMD account.


Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"